BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 10518230)

  • 1. Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera.
    Kuhn L; Denny L; Pollack AE; Wright TC
    Contraception; 1999 Jun; 59(6):363-7. PubMed ID: 10518230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy.
    Mauck CK; Callahan MM; Baker J; Arbogast K; Veazey R; Stock R; Pan Z; Morrison CS; Chen-Mok M; Archer DF; Gabelnick HL
    Contraception; 1999 Jul; 60(1):15-24. PubMed ID: 10549448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
    Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
    Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents.
    Jacobson DL; Peralta L; Farmer M; Graham NM; Gaydos C; Zenilman J
    Sex Transm Dis; 2000 Jul; 27(6):313-9. PubMed ID: 10907905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depo Provera: a profile of current users.
    Jarman H; Kovacs GT; Westcott M
    Aust N Z J Obstet Gynaecol; 1990 Feb; 30(1):74-6. PubMed ID: 2140675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depressive symptoms and Depo-Provera.
    Westhoff C; Truman C; Kalmuss D; Cushman L; Davidson A; Rulin M; Heartwell S
    Contraception; 1998 Apr; 57(4):237-40. PubMed ID: 9649914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depo-Provera: a critical analysis.
    Minkin S
    Women Health; 1980; 5(2):49-69. PubMed ID: 6451987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
    Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z
    J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depo Provera: still controversial.
    Wren LM
    Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina.
    Mostad SB; Overbaugh J; DeVange DM; Welch MJ; Chohan B; Mandaliya K; Nyange P; Martin HL; Ndinya-Achola J; Bwayo JJ; Kreiss JK
    Lancet; 1997 Sep; 350(9082):922-7. PubMed ID: 9314871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depo-Provera--ethical issues in its testing and distribution.
    Potts M; Paxman JM
    J Med Ethics; 1984 Mar; 10(1):9-20. PubMed ID: 6231379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives.
    Moore LL; Valuck R; McDougall C; Fink W
    Contraception; 1995 Oct; 52(4):215-9. PubMed ID: 8605778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case for concern?
    Gartland A
    Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In utero exposure to steroid contraceptives and outcome of pregnancy.
    Pardthaisong T; Gray RH
    Am J Epidemiol; 1991 Oct; 134(8):795-803. PubMed ID: 1835282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depo-Provera: just another contraceptive?
    Jones M
    Fertil Contracept; 1978 Apr; 2(2):26-9. PubMed ID: 12336094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medroxyprogesterone acetate [Depo Provera] injections. Development of striae.
    Gupta M
    Br J Fam Plann; 2000 Apr; 26(2):104-5. PubMed ID: 10773604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.